An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular CarcinomaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers investigated whether the gut microbiome is associated with the efficacy of immune checkpoint inhibitors (ICI) in patients with hepatocellular carcinoma (HCC), a link previously shown in other cancers but not yet tested in HCC.
How was it studied?
Thirty-six HCC patients scheduled for ICI were enrolled prospectively. Fecal samples were collected at baseline and 8 weeks later, with 20 patients providing both. Gut microbiome was assessed via 16S rRNA sequencing and shotgun whole-genome sequencing, then correlated with objective response, disease control, and overall survival.
What did they find?
Baseline microbiome diversity, richness, and composition did not differ between responders and nonresponders, or between disease-control and non-disease-control groups. Immunotherapy did not change major microbiome features over 8 weeks. No taxa were enriched with objective response, though Bifidobacterium, Coprococcus, and Acidaminococcus were enriched in patients achieving disease control; none predicted overall survival.
Why it matters
This exploratory study found no overt association between gut microbiome and ICI efficacy in HCC, unlike patterns reported in other cancers. The authors call for a larger prospective study before drawing definite conclusions.